Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377)
Eshleman, S. H., Krogstad, P., Jackson, J. B., Wang, Y-G., Lee, S., Wei, L. J., Cunningham, S., Wantman, M., Wiznia, A., Johnson, G., Nachman, S., & Palumbo, P. (2001) Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377). Journal of Infectious Diseases, 183(12), pp. 1732-1738.
In Pediatric AIDS Clinical Trials Group 377, antiretroviral therapy-experienced children were randomized to 4 treatment arms that included different combinations of stavudine, lamivudine (3TC), nevirapine (Nvp), nelfinavir (Nfv), and ritonavir (Rtv). Previous treatment with zidovudine (Zdv), didanosine (ddI), or zalcitabine (ddC) was acceptable. Drug resistance ((R)) mutations were assessed before study treatment (baseline) and at virologic failure. Zdv(R), ddI(R), and ddC(R) mutations were detected frequently at baseline but were not associated with virologic failure. Children with drug resistance mutations at baseline had greater reductions in virus load over time than did children who did not. Nvp(R) and 3TC(R) mutations were detected frequently at virologic failure, and Nvp(R) mutations were more common among children receiving 3-drug versus 4-drug Nvp-containing regimens. Children who were maintained on their study regimen after virologic failure accumulated additional Nvp(R) and 3TC(R) mutations plus Rtv(R) and Nfv(R) mutations. However, Rtv(R) and Nfv(R) mutations were detected at unexpectedly low rates.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Additional Information:||ISI Document Delivery No.: 439HW Times Cited: 28 Cited Reference Count: 26 Eshleman, SH Krogstad, P Jackson, JB Wang, YG Lee, S Wei, LJ Cunningham, S Wantman, M Wiznia, A Johnson, G Nachman, S Palumbo, P Univ chicago press Chicago|
|Keywords:||randomized controlled trial, vertical transmission, antiretroviral, therapy, lamivudine resistance, protease inhibitors, replicative, fitness, zidovudine, mutation, infection, management|
|Divisions:||Current > QUT Faculties and Divisions > Science & Engineering Faculty|
|Copyright Owner:||Copyright 2001 Infectious Diseases Society of America|
|Deposited On:||20 Nov 2015 04:24|
|Last Modified:||20 Nov 2015 04:24|
Repository Staff Only: item control page